期刊文献+

阿立哌唑与利培酮治疗精神分裂症对照研究 被引量:1

Comparative study of Aripiprazole and Risperidone in the treatment of schizophrenia
下载PDF
导出
摘要 目的:比较阿立哌唑与利培酮治疗精神分裂症的临床疗效和不良反应。方法:将95例精神分裂症患者随机分为两组,分别给予阿立哌唑(阿立哌唑组)与利培酮(利培垌组)治疗12周。用阳性和阴性综合征量表(PANSS)和治疗中需处理的不良反应症状量表(TESS)作为评定指标,分别于治疗前后评定疗效和不良反应。结果:阿立哌唑组总有效率和临床治愈率分别为79.74%、56.67%,明显高于利培酮组的61.05%、29.47%,两组PANSS评分治疗后均显著下降(P<0.01),阿立哌唑组治疗中减分率及治疗中的不良反应明显低于利培酮组(P<0.05)。结论:在精神分裂症的治疗中,阿立哌唑的总有效率、治愈率优于利培酮,且不良反应低、依从性好。 Objective: To compare the efficacy and adverse reactions of Aripip^azole and Risperidone in the treatment of schizophrenia. Meth- ods:95 patients with schizophrenia were randomly divided into two groups ,were given Aripiprazole or Risperidonefor treatment of 12 weeks. The Positive and Negative Syndrome Scale (PANSS) and the Treatment Emergent Side Effect Scale (TESS) were used to assess the clinical efficacy and the adverse reaction respectively before and after the treatment. Results: The total efficiency rates and the clinical cure rate in the Aripiprazole group were 79.74% and 56.67% respectively, obviously higher than those in the Risperidone group (61.05 % and 29.47 % ), two groups of PANSS score were significantly de- creased after treatment (P 〈 0.01 ), in the treatment, the reduction rate and adverse reaction of the Aripiprazole group were obviously higher than the Ris- peridone group ( P 〈 0.05 ). Conclusion : In the treatment of schizophrenia, the total efficiency rates and the clinical cure rate of Aripiprazole were better than Risperidone, and has low adverse reactions and good compliance.
作者 刘大威
出处 《中国民康医学》 2013年第24期8-8,24,共2页 Medical Journal of Chinese People’s Health
关键词 阿立哌唑 利培酮 精神分裂症 Aripiprazole Risperidone Schizophrenia
  • 相关文献

参考文献6

二级参考文献33

  • 1Kilkuchiet T,et al:J Pharmacol Exp Ther.1995;274(1):329—336.
  • 2Semba J,et al:Neuropharmacology,1995;34(7):785—791.
  • 3Fujikawa M,et al:Pharmacol Biochem Behav.1996;53(4):903—909.
  • 4Alison P,et al:Molecular Brain Research,1998;55:285—292.
  • 5Inoue A。et al:Brain Res Mol Brain Res.1998;55:285—292.
  • 6Shapine DA,et al:Neuropsychopharmacology,2003:1 46(5):214—216.
  • 7Bruce S:Drugs Research and Development,1999;2(1):47—48.
  • 8Stephen M,et al:Drugs oI the Future,2000;25(9):961—963.
  • 9Susman ED:Drugs oI the Future,1997;22(9):1029—1030.
  • 10McGavin JK,et al:CNS Drugs,2002;16(11):779—788.

共引文献469

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部